Back to catalogue
№ 309 7 filings · 2025-03-12 → 2026-06-24

RIVER GLOBAL PLC

RVRB
Financial Services Share price 40.50p Market cap £8.47m Overall fit 320 /1000

Not an AI beneficiary and offers only indirect operating leverage; value case rests on a wide but structural discount to a management-set NAV, with acceptable balance-sheet quality but weak growth momentum in the parent group.

Fair value range 40p–55p Mid case · £9.90m
Absolute upside +16.9% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • Board's Parmenion £75-90m valuation reviewed with advisers and backed by growing audited financials
  • Loan-note coupon (£2.6m annualised) provides contractual income floor
  • Parmenion 2024 EBITDA £20.1m up from £17.9m demonstrates underlying growth
Limits the call
  • Material discrepancy between disclosed 143.94m B-share count and 20.9m shares in the price feed makes per-share value sensitive to share-count assumption
  • No announced monetisation path or dividend policy for Parmenion stake — the discount may prove permanent
  • Non-voting B shares limit shareholder influence over any exit
Methodology

Look-through NAV of 30% Parmenion stake, with holding-company discount and loan-note income cross-check

In one line · bull case

A cheap listed proxy for a 30% stake in Parmenion, a scaling UK adviser platform, trading at a very wide discount to management's own £75-90m NAV mark.

In one line · biggest risk

Non-voting minority stake in a private business with no announced exit — the holding-company discount could prove structural rather than temporary.

Drivers
AI beneficiary 15 /100
Asset & wealth manager; no meaningful position in AI supply chain and no disclosed AI-driven revenue uplift at Parmenion or the active-equities arm.
Operating leverage 55 /100
Parmenion is a high-fixed-cost platform (£1.5m revenue in 2024 drove ~£2m more EBITDA), but RVRB captures this indirectly via the equity mark not the loan-note coupon.
Earnings vs expectations 30 /100
Group has repeatedly slipped 'tantalisingly close to profitability' targets over multiple periods (FY24, H1 25); Parmenion side has been broadly in line.
Growth momentum 30 /100
Active-equities AUM shrinking (H1 25 £2.17bn vs. £2.37bn a year earlier); Parmenion (B side) growing well but not the reported entity.
Moat 30 /100
Parmenion has some platform scale/switching cost, but the wider asset-management arm is a small player in a competitive commoditising industry.
Earnings quality 40 /100
Cash losses persist at the parent with recurring restructuring exceptionals; loan-note interest is non-cash (received as additional notes) which flatters accrual EBITDA on the B side.
Management quality 40 /100
Gilbert brings pedigree but the group has restructured repeatedly since the AssetCo era; consolidation execution has been slow and acquisitive strategy dilutes A holders.
Cyclicality 65 /100
AUM-linked revenue on both A and B sides makes results sensitive to equity market levels and fund flows.
Leverage 15 /100
Group holds cash (H1 25: £8.5m) and no material debt; regulatory capital requirement ~£4.5m — fortress-lite balance sheet.
Value-trap signals · 4
  • Complex A/B share split executed to force market re-rating, which has not occurred
  • Recurring restructuring charges each half (~£1m per period)
  • No dividend and no announced Parmenion monetisation timetable
  • Non-voting share class limits any minority-shareholder influence

RIVER GLOBAL PLC (RVRB) — Investment Research Note

Executive summary

RVRB (B Shares) is a listed proxy for a 30% structured equity interest in Parmenion, a growing UK adviser wealth-management platform (~£13.1bn AUM, £50.2m 2024 revenue, £20.1m 2024 EBITDA); the wider group also holds an AIM-listed active equities asset manager (represented by the A Ordinary Shares, RVRG). Over the last two years the group's active equities arm has been shrinking (AUM £2.37bn → £2.17bn, revenue £6.9m → £6.1m per half) while Parmenion has compounded (AUM +£2bn to £13.1bn in 2024). The single most important valuation point today is the delta between the board's own valuation of the Parmenion stake (£75–90m) and RVRB's very small quoted market cap — the entire investment case hinges on whether the market eventually re-rates the B shares toward that intrinsic value or whether structural discount, non-voting status and eventual disposal risk keep the discount permanent.

Fair value estimate

Methodology: NAV / look-through valuation of the Parmenion loan-notes-and-equity structure, using the board's stated £75–90m fair value for the 30% Parmenion interest (source: 2025 half-year report), discounted for (i) non-voting share status, (ii) closed-end structure and illiquidity, (iii) minority holding in a private company, and (iv) execution risk on any monetisation event. I cross-check against the accrued interest income (£2.6m annualised) — at a mid-teens multiple this supports ~£40m of stand-alone value on the loan-note stream alone.

Applying a 25–35% holding-company discount to the board's £75–90m range gives an equity value of ~£50–72m for the B share pool. Divided across the 143.94m B shares in issue disclosed at 6 October 2025 (per the Devon Equity acquisition notice), this implies ~35p–50p per B share, mid ~42p. Applying a milder 15–20% discount stretches the top end to ~55p.

  • Fair value range: 40p – 55p per B share (mid ~47p)
  • Implied mid market cap: ~£68m on 143.94m B shares in issue, but ~£9.9m on the 20.9m share-count implied by the disclosed £8.8m market cap.
  • Current market cap: £8.8m at 42p (per market data), which is a very significant discount if the true share count is 143.94m; on a per-share basis vs. the fair value mid (~47p) upside is ~13%.

Important caveat: the £8.8m market cap and 20.9m shares-outstanding provided cannot be reconciled with the 143.94m B shares in issue disclosed in the October 2025 filing. If the disclosed share count is authoritative, market cap of the B pool should be closer to ~£60m at 42p and the stock would still trade at a ~30% discount to the board's Parmenion valuation. Investors should verify current share count before sizing.

Sector context

Correctly classified as Financial Services (asset & wealth management, ICB Financials). RVRB's economic exposure is dominated by Parmenion, an adviser platform — comparable UK peers include AJ Bell, Nucleus Financial (now James Hay/NFS), Quilter (WealthSelect platform), and platform-adjacent Hargreaves Lansdown (private). RVRB's quality profile is below listed platform peers (minority stake, no control, no dividend visibility, closed-end vehicle discount) but the underlying Parmenion economics look competitive: 2024 AUM growth ~18%, operating margin ~35%, EBITDA growth ~12% year-on-year.

Investment thesis

  1. Deep discount to management's own Parmenion valuation. The board's £75–90m mark on the 30% stake implies material upside vs. the quoted market cap even with a punitive holding-company discount 2025-06-30 half-year. Parmenion's 2024 growth (AUM +£2bn to £13.1bn, EBITDA £17.9m → £20.1m) suggests the mark, if anything, is conservative rather than stretched.
  2. Contracted, growing cash yield from the Parmenion loan notes. The B share economics include £2.6m of annualised loan-note interest (H1 2025: £1.3m, up from £1.2m) that provides visible income backing the value 2025-06-30 half-year. This stream is contractual, growing modestly, and doesn't depend on the volatile active-equities arm.
  3. Underlying platform has a structural tailwind. Parmenion supported a £1.5bn platform-switch pipeline for 2025 and released 400+ product enhancements in 2024, reflecting a scale-economics business that continues to gain share in a consolidating UK adviser platform market 2025-06-30 half-year.

Key risks

  1. Non-controlling minority in a private company with no defined exit. The 30% Parmenion interest cannot be sold independently on the market and there is no announced liquidity event; the discount may be permanent 2025-06-30 half-year.
  2. Non-voting shares, complex capital structure. The B shares have no voting rights and rely entirely on board decisions about how and when Parmenion value is monetised or distributed, which historically has moved slowly at this group (formerly AssetCo/River & Mercantile) 2025-10-02 acquisition notice; 2025-06-30 half-year.
  3. Central-cost allocation and going-concern optics. The parent still carries loss-making activities on the A side (H1 2025 EBITDA loss £1.5m) and central costs are recharged partly to B — deterioration in the A business could erode B-share value through recharges or forced capital top-ups 2025-06-30 half-year, going-concern note.

Operating leverage

Parmenion is a high-operating-leverage wealth platform: 2024 revenue £50.2m (+3% YoY) generated EBITDA £20.1m (+12% YoY) and operating profit £17.5m vs. £15.5m — every ~£1.5m of incremental revenue drove roughly £2m more EBITDA, an incremental margin well above 100% in that comparison, reflecting the fixed-cost nature of platform infrastructure. AUM grew ~18% (£11.1bn → £13.1bn), suggesting revenue lag but strong future flow-through as AUM re-prices. However, RVRB shareholders capture this leverage only indirectly via the fixed-coupon loan notes plus the equity stake mark; the loan-note coupon does not scale with Parmenion revenue, so the operating leverage flows to the equity mark rather than to cash yield. On the A-share side (which does not accrue to RVRB), the active-equities business has typical asset-management operating leverage — H1 2025 revenue fell £0.8m but EBITDA loss halved, evidence of large fixed cost cuts biting.

Value-trap signals

  • Complex, opaque capital structure with a share-split (A/B) executed in March 2025 explicitly to allow the market to value Parmenion separately — yet the market has still not narrowed the discount 2025-06-30 half-year.
  • Repeated restructurings and ongoing losses at the parent (H1 2025 restructuring charge £1.05m, following £0.97m the prior half) — evidence of persistent transformation costs 2025-06-30 half-year.
  • No dividend, no announced monetisation timetable for the Parmenion stake, and continuing acquisitions (Devon, ODAM) financed largely in shares, diluting A holders (though not B holders' economic claim on Parmenion).
  • Non-voting B shares structurally limit shareholder influence over any Parmenion sale terms.

Earnings vs. expectations

The filings contain no consensus estimates, but management has repeatedly signalled that consolidated profitability is "tantalisingly close" (June 2025 chairman letter) and yet again missed it in H1 2025 — the pattern across FY24 and H1 25 is one of losses narrower than the prior period but slippage against the "run-rate profitability" target the chairman has flagged for multiple reporting cycles. On the B-share/Parmenion side, results have modestly exceeded prior periods (2024 EBITDA £20.1m vs. £17.9m in 2023). Overall: A side chronically missing its own profitability guidance; B side delivering broadly in line to modestly ahead.

Conviction

3 / 5 — moderate.

Anchors: (i) the board's Parmenion valuation is fresh and reviewed with advisers; (ii) Parmenion has three years of audited, growing financials underneath it; (iii) the loan-note coupon gives an income floor.

Caveats: (i) the discount from intrinsic to market is very wide, which usually signals either a data error, a structural reason for the discount, or a market mispricing — hard to know which; (ii) there is a material discrepancy between the disclosed 143.94m B-share count (October 2025 notice) and the 20.9m share count / £8.8m market cap in the price feed, which materially changes any per-share fair-value figure; (iii) no announced monetisation path for the Parmenion stake means the discount could persist indefinitely.

Filings consulted · 7

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-06-24Update ON Disposal Amp Assets Under Management Aum2026-06-24_9632979_update-on-disposal-amp-assets-under-management-aum.md0.75
  2. 2026-03-31Result OF Agm2026-03-31_9501054_result-of-agm.md0.30
  3. 2026-03-06Notice OF Final Results Amp Annual General Meeting2026-03-06_9463227_notice-of-final-results-amp-annual-general-meeting.md1.00
  4. 2025-10-02Acquisition OF Devon Equity Management Limited2025-10-02_9146356_acquisition-of-devon-equity-management-limited.md0.64
  5. 2025-06-30Acquisition OF Devon Equity Management2025-06-30_8953486_acquisition-of-devon-equity-management.md0.49
  6. 2025-06-302025 Half Year Report2025-06-30_8953272_2025-half-year-report.md0.58
  7. 2025-03-12Notice OF Agm2025-03-12_8776155_notice-of-agm.md0.20

This research note was authored by a large language model after reading 7 regulatory filings published between 2025-03-12 and 2026-06-24. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.